Holding(s) in Company


TR-1: Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i
 
1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:Summit Therapeutics PLC
Sedol BN40HZ0
1b. Please indicate if the issuer is a non-UK issuer  (please mark with an “X” if appropriate)
Non-UK issuer 
2. Reason for the notification (please mark the appropriate box or boxes with an “X”)
An acquisition or disposal of voting rights 
An acquisition or disposal of financial instruments 
An event changing the breakdown of voting rightsX
Other (please specify)iii: 
3. Details of person subject to the notification obligationiv
Name1Lansdowne Partners International Limited

2Lansdowne Partners Limited

3Lansdowne Partners (UK) LLP
City and country of registered office (if applicable)London, United Kingdom
4. Full name of shareholder(s) (if different from 3.)v
Name 

HSBC Client Holdings Nominee (UK) Ltd
HSBC Bank Plc Lansdowne Markets

 

(Registered Shareholders)

 
City and country of registered office (if applicable)N/A
5. Date on which the threshold was crossed or reachedvi:24/12/2019
6. Date on which issuer notified (DD/MM/YYYY):27/12/2019
7. Total positions of person(s) subject to the notification obligation
 % of voting rights attached to shares (total of 8. A)% of voting rights through financial instruments
(total of 8.B 1 + 8.B 2)
Total of both in % (8.A + 8.B)Total number of voting rights of issuervii
Resulting situation on the date on which threshold was crossed or reached3.92%2.38%6.30%335,873,208
Position of previous notification (if
applicable)
8.21%4.98%13.18% 



8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii
A: Voting rights attached to shares
Class/type of
shares

ISIN code (if possible)
Number of voting rightsix% of voting rights
Direct
(Art 9 of Directive 2004/109/EC) (DTR5.1)
Indirect
(Art 10 of Directive 2004/109/EC) (DTR5.2.1)
Direct
(Art 9 of Directive 2004/109/EC) (DTR5.1)
Indirect
(Art 10 of Directive 2004/109/EC) (DTR5.2.1)
GB00BN40HZ01 13,160,170 3.92%
     
     
SUBTOTAL 8. A13,160,1703.92%
 

 
B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))
Type of financial instrumentExpiration
date
x
Exercise/
Conversion Period
xi
Number of voting rights that may be acquired if the instrument is
exercised/converted.
% of voting rights
American Depositary Shares (ADS)N/AN/A7,983,3302.38%
  SUBTOTAL 8. B 17,983,3302.38%
 

 
B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))
Type of financial instrumentExpiration
date
x
Exercise/
Conversion Period
xi
Physical or cash
settlementxii
Number of voting rights % of voting rights
      
      
   SUBTOTAL 8.B.2  
 

 

 


9. Information in relation to the person subject to the notification obligation (please mark the
applicable box with an “X”)
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii 
Full chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)
X
Namexv% of voting rights if it equals or is higher than the notifiable threshold% of voting rights through financial instruments if it equals or is higher than the notifiable thresholdTotal of both if it equals or is higher than the notifiable threshold
Lansdowne Partners
International Limited
3.92%2.38%6.30%
Lansdowne Partners
Limited
   
Lansdowne Partners (UK) LLP3.92%2.38%6.30%
 
10. In case of proxy voting, please identify:
Name of the proxy holder 
The number and % of voting rights held 
The date until which the voting rights will be held 
 
11. Additional informationxvi
This disclosure is being made as a result of the increase in share capital announced by the company and not a as a result of any trading activity by Lansdowne Partners (UK) LLP.


Place of completionLondon
Date of completion27 December 2019